• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Emergent BioSolutions Names Joseph C. Papa As CEO


Papa will take over the over effective immediately.

Emergent BioSolutions

Emergent BioSolutions

Joseph C. Papa is the new CEO of Emergent BioSolutions.

Papa will step into the role as of February 21, 2024, according to a press release from the company.1 He is taking over from interim CEO Haywood Miller.

Emergent Biosolution's lead product is the Narcan Nasal Spray, an over-the-counter opioid overdose treatment.

In a press release, Papa said, “Whether it’s increasing access to Narcan® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver important medical countermeasures to customers around the world, Emergent is providing critical products to address global health crises. I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness. I look forward to working with the team to accelerate the company’s progress, continue improving its financial position and drive value for shareholders. It is a privilege to join Emergent and chart a new chapter in this vital space.”

According to the press release, Papa will focus on returning the company to growth while also making moves to pay down the company’s debt. Prior to joining Emergent, Papa served as CEO at Bausch and Lomb Corporation, where he led the company’s IPO. At the time, the company was able to raise $630 million under Papa’s leadership.

In the same press release, Emergent’s chairman of the board of directors Zsolt Harsanyi, Ph.D., said, “Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent. He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry. Joe has a solid track record of driving growth and successfully navigating companies through periods of transformation. His leadership will be instrumental in strengthening Emergent’s balance sheet and returning to growth, as we continue to deliver on our mission to protect and enhance life. On behalf of the Board, I would also like to thank Haywood Miller for his leadership and contributions during this interim period.”

Haywood Miller, the interim CEO, said that he was encouraged by the company’s ability to strengthen in financial foundation in recent months. ““It has been an honor to lead Emergent during this period of transition, and I am confident the company is well positioned for the future as a leader in global preparedness and public health,” he said.


  1. Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO. Emergent. February 21, 2024. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-appoints-industry-leader-joseph-c-papa-new
Related Videos
Related Content